


## APPRAISAL PROCESS: OVERVIEW



\* No fixed timescale can be given for consideration of AWMSG's advice by Welsh Government, as it is dependent on competing Welsh Government priorities.

## Detailed summary

**Step 1:** Pharmaceutical company provides information on new (licensed) medicine.

**Step 2:** A draft report is prepared by the All Wales Therapeutics and Toxicology Centre (AWTTC) assessing clinical and cost-effectiveness. The company is invited to comment on the draft report. In addition, patients, carers, patient organisations and clinical experts are invited to give their views on the medicine.

**Step 3:** A subgroup of AWMSG, the New Medicines Group (NMG), meet in private to consider:

- information from the company
- draft report from AWTTC
- company response to draft report
- patient/carer/patient organisation views, and
- clinical expert opinion.

The draft report is finalised and a preliminary recommendation is agreed. The company is invited to comment on the recommendation.

**Step 4:** Prior to the AWMSG meeting, relevant papers are posted on the website (patient/carer/patient organisation views remain confidential and are not available on the website).

AWMSG meet in public to consider:

- final report from AWTTC
- preliminary recommendation from NMG
- company response to preliminary recommendation
- patient/carer/patient organisation views, and
- clinical expert opinion.

Unlike NMG, AWMSG considers budget impact and the broader impact on society, in addition to clinical and cost-effectiveness.

A final recommendation is agreed in private and is subsequently announced in public at the meeting.

**Step 5:** Following acceptance from the company, AWMSG advises Welsh Government. Welsh Government takes account of this advice and decides whether or not the medicine should be made routinely available in NHS Wales. No fixed timescale can be given for this decision, as it is dependent on competing Welsh Government priorities.

**Step 6:** Medicines recommended for use (for the disease or condition considered) are made routinely available in the NHS across Wales within two months. Medicines not recommended for use (for the disease or condition considered) will **not** be routinely available in the NHS across Wales.